Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-10

AUTHORS

Ivy Song, Julie Borland, Shuguang Chen, Phyllis Guta, Yu Lou, David Wilfret, Toshihiro Wajima, Paul Savina, Amanda Peppercorn, Stephen Castellino, David Wagner, Louise Hosking, Michael Mosteller, Justin P. Rubio, Stephen C. Piscitelli

ABSTRACT

PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects. METHODS: The first study was an open-label crossover where 12 subjects received DTG 50 mg every 24 hours (q24h) for 5 days, followed by DTG 50 mg and EFV 600 mg q24h for 14 days. The second study was an open-label crossover where 18 subjects received DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg every 12 hours (q12h) for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days. Safety assessments and serial PK samples were collected. Non-compartmental PK analysis and geometric mean ratios and 90% confidence intervals were generated. RESULTS: The combination of DTG with EFV or TPV/r was generally well tolerated. Four subjects discontinued the TPV/r study due to increases in alanine aminotransferase that were considered related to TPV/r. Co-administration with EFV resulted in decreases of 57, 39 and 75% in DTG AUC(0-τ), Cmax and Cτ, respectively. Co-administration with TPV/r resulted in decreases of 59, 46 and 76% in DTG AUC(0-τ), Cmax and Cτ, respectively. CONCLUSIONS: Given the reductions in exposure and PK/pharmacodynamic relationships in phase II/III trials, DTG should be given at an increased dose of 50 mg twice daily when co-administered with EFV or TPV/r, and alternative regimens without inducers should be considered in integrase inhibitor-resistant patients. More... »

PAGES

1173-1179

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8

DOI

http://dx.doi.org/10.1007/s00228-014-1732-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043400137

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25146692


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-HIV Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoxazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Integrase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heterocyclic Compounds, 3-Ring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Biological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ritonavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Song", 
        "givenName": "Ivy", 
        "id": "sg:person.0741434051.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741434051.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Borland", 
        "givenName": "Julie", 
        "id": "sg:person.0575606363.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575606363.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Shuguang", 
        "id": "sg:person.01272345137.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272345137.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418236.a", 
          "name": [
            "GlaxoSmithKline, Stockley Park, Uxbridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guta", 
        "givenName": "Phyllis", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lou", 
        "givenName": "Yu", 
        "id": "sg:person.01075710535.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075710535.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilfret", 
        "givenName": "David", 
        "id": "sg:person.07374132774.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07374132774.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shionogi (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.419164.f", 
          "name": [
            "Shionogi & Co., Ltd., Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wajima", 
        "givenName": "Toshihiro", 
        "id": "sg:person.01364605124.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364605124.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Savina", 
        "givenName": "Paul", 
        "id": "sg:person.0731212511.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731212511.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peppercorn", 
        "givenName": "Amanda", 
        "id": "sg:person.01316471724.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316471724.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castellino", 
        "givenName": "Stephen", 
        "id": "sg:person.01002361140.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002361140.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wagner", 
        "givenName": "David", 
        "id": "sg:person.01317322142.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317322142.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418236.a", 
          "name": [
            "GlaxoSmithKline, Stevenage, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hosking", 
        "givenName": "Louise", 
        "id": "sg:person.01137555054.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137555054.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mosteller", 
        "givenName": "Michael", 
        "id": "sg:person.01234343615.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234343615.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418236.a", 
          "name": [
            "GlaxoSmithKline, Stevenage, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rubio", 
        "givenName": "Justin P.", 
        "id": "sg:person.011235763662.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011235763662.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Piscitelli", 
        "givenName": "Stephen C.", 
        "id": "sg:person.01100274674.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100274674.19"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1128/aac.05739-11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006959899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(11)70290-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012328949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00842-09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012666122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318276cda9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013562829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318276cda9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013562829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318276cda9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013562829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/js970486q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014403362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270010371113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017710989"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.antiviral.2009.09.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022449206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(13)61221-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022615950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00073-11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025297073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2011.03947.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028679510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318183a982", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030792638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318183a982", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030792638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.112.048918", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045191601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61853-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045841940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00292-13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046871169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200140120-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048700706", 
          "https://doi.org/10.2165/00003088-200140120-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200140120-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048700706", 
          "https://doi.org/10.2165/00003088-200140120-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7448/ias.15.6.18112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049897586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.01486-08", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050895815"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1310/rrx7-49me-27v7-mwwv", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064986057"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1310/rrx7-49me-27v7-mwwv", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064986057"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-10", 
    "datePublishedReg": "2014-10-01", 
    "description": "PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects.\nMETHODS: The first study was an open-label crossover where 12 subjects received DTG 50 mg every 24 hours (q24h) for 5 days, followed by DTG 50 mg and EFV 600 mg q24h for 14 days. The second study was an open-label crossover where 18 subjects received DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg every 12 hours (q12h) for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days. Safety assessments and serial PK samples were collected. Non-compartmental PK analysis and geometric mean ratios and 90% confidence intervals were generated.\nRESULTS: The combination of DTG with EFV or TPV/r was generally well tolerated. Four subjects discontinued the TPV/r study due to increases in alanine aminotransferase that were considered related to TPV/r. Co-administration with EFV resulted in decreases of 57, 39 and 75% in DTG AUC(0-\u03c4), Cmax and C\u03c4, respectively. Co-administration with TPV/r resulted in decreases of 59, 46 and 76% in DTG AUC(0-\u03c4), Cmax and C\u03c4, respectively.\nCONCLUSIONS: Given the reductions in exposure and PK/pharmacodynamic relationships in phase II/III trials, DTG should be given at an increased dose of 50 mg twice daily when co-administered with EFV or TPV/r, and alternative regimens without inducers should be considered in integrase inhibitor-resistant patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00228-014-1732-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "70"
      }
    ], 
    "name": "Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir", 
    "pagination": "1173-1179", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "cebb2057897e46861b5d520c8c6df7cad23cc8a3d453de92848f861b6ca83936"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25146692"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-014-1732-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043400137"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-014-1732-8", 
      "https://app.dimensions.ai/details/publication/pub.1043400137"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89819_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00228-014-1732-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'


 

This table displays all metadata directly associated to this object as RDF triples.

323 TRIPLES      21 PREDICATES      66 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-014-1732-8 schema:about N036a05c7442c41359de7951845c0c92e
2 N082a84bbb1624a7cb7067f3074f7ecd1
3 N0c29dafb559344d39cfc2bf9be05433d
4 N1054114c74f74009a5eccf44e05b1fc3
5 N1defc64d4dc04cb88c0fc4aad9c9a2e6
6 N3e0715a8abd149ab8975c144acedf636
7 N43e5cddf19eb46e98a8791a87b063a58
8 N4ab2d2dc28324157a48bccedcb0cb62d
9 N521ead0d74cb4769a727f7787af7ad69
10 N52270c680b4b4ba3bdce67c34f79a65a
11 N983e69f1d641453bbca58990ff3ec23d
12 N9bf9efc16f4d42b8b347e0f005fd133a
13 Nbe4eaa820c4243c6acf710f5ea214c9e
14 Nc863e6e0e7b74d19b462c5ad24b38e9e
15 Ndfb56bb01dca4e46b42d9d4747d781d6
16 Ndfc0208c24b1420b9aaefdd133e27643
17 Ne3c8f1b6cf254c0ca39027bb604bc7a5
18 Neb764dcf03eb46f48c7251e6f3cb1096
19 Nf1852d3f52f94307a71b0686e48664b5
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N5b15802c52314a059c051fefef9d0c21
23 schema:citation sg:pub.10.2165/00003088-200140120-00002
24 https://doi.org/10.1016/j.antiviral.2009.09.001
25 https://doi.org/10.1016/s0140-6736(12)61853-4
26 https://doi.org/10.1016/s0140-6736(13)61221-0
27 https://doi.org/10.1016/s1473-3099(11)70290-0
28 https://doi.org/10.1021/js970486q
29 https://doi.org/10.1097/qai.0b013e318183a982
30 https://doi.org/10.1097/qai.0b013e318276cda9
31 https://doi.org/10.1111/j.1365-2125.2011.03947.x
32 https://doi.org/10.1124/dmd.112.048918
33 https://doi.org/10.1128/aac.00073-11
34 https://doi.org/10.1128/aac.00292-13
35 https://doi.org/10.1128/aac.00842-09
36 https://doi.org/10.1128/aac.01486-08
37 https://doi.org/10.1128/aac.05739-11
38 https://doi.org/10.1177/0091270010371113
39 https://doi.org/10.1310/rrx7-49me-27v7-mwwv
40 https://doi.org/10.7448/ias.15.6.18112
41 schema:datePublished 2014-10
42 schema:datePublishedReg 2014-10-01
43 schema:description PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects. METHODS: The first study was an open-label crossover where 12 subjects received DTG 50 mg every 24 hours (q24h) for 5 days, followed by DTG 50 mg and EFV 600 mg q24h for 14 days. The second study was an open-label crossover where 18 subjects received DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg every 12 hours (q12h) for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days. Safety assessments and serial PK samples were collected. Non-compartmental PK analysis and geometric mean ratios and 90% confidence intervals were generated. RESULTS: The combination of DTG with EFV or TPV/r was generally well tolerated. Four subjects discontinued the TPV/r study due to increases in alanine aminotransferase that were considered related to TPV/r. Co-administration with EFV resulted in decreases of 57, 39 and 75% in DTG AUC(0-τ), Cmax and Cτ, respectively. Co-administration with TPV/r resulted in decreases of 59, 46 and 76% in DTG AUC(0-τ), Cmax and Cτ, respectively. CONCLUSIONS: Given the reductions in exposure and PK/pharmacodynamic relationships in phase II/III trials, DTG should be given at an increased dose of 50 mg twice daily when co-administered with EFV or TPV/r, and alternative regimens without inducers should be considered in integrase inhibitor-resistant patients.
44 schema:genre research_article
45 schema:inLanguage en
46 schema:isAccessibleForFree true
47 schema:isPartOf N6b45d64f548948759b428404862ac4f0
48 Nf1911e3edd2a4edf97f3bc21bad8c3e0
49 sg:journal.1054337
50 schema:name Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
51 schema:pagination 1173-1179
52 schema:productId N213d75314df54341895a51907c2c561e
53 N39b59388255249f99628d713bae625f4
54 N6a87277eaa0d474aaf8d67035ef3acfe
55 N7b15bfe779074162936ef2cd2f8af0d2
56 Ncf43988fcb83402d8fcb8114bf29df81
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043400137
58 https://doi.org/10.1007/s00228-014-1732-8
59 schema:sdDatePublished 2019-04-11T10:01
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher N6a880b05500a4a9ca6c2f7be9fade2ee
62 schema:url http://link.springer.com/10.1007/s00228-014-1732-8
63 sgo:license sg:explorer/license/
64 sgo:sdDataset articles
65 rdf:type schema:ScholarlyArticle
66 N01a032debbd04ec0a0781e0925aac432 rdf:first N488739562830472faa5c567065dcb6a0
67 rdf:rest N5728cbc9224c4d0799dd3c5b0c51abf2
68 N036a05c7442c41359de7951845c0c92e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Pyrones
70 rdf:type schema:DefinedTerm
71 N082a84bbb1624a7cb7067f3074f7ecd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Young Adult
73 rdf:type schema:DefinedTerm
74 N0bc4ab2127e843ccb4cc8df6e27fb5cf schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
75 rdf:type schema:Organization
76 N0c29dafb559344d39cfc2bf9be05433d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Humans
78 rdf:type schema:DefinedTerm
79 N0f93e99dc71d4f0c9948dfe518fbc695 rdf:first sg:person.01234343615.46
80 rdf:rest N84511853986a4a0088fcdd14f0f5c072
81 N1054114c74f74009a5eccf44e05b1fc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Adult
83 rdf:type schema:DefinedTerm
84 N14b058f26c5540c285571de86d29c9a8 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
85 rdf:type schema:Organization
86 N1defc64d4dc04cb88c0fc4aad9c9a2e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Pyridines
88 rdf:type schema:DefinedTerm
89 N213d75314df54341895a51907c2c561e schema:name dimensions_id
90 schema:value pub.1043400137
91 rdf:type schema:PropertyValue
92 N2dba33752edc4092a6500ef38cac999b rdf:first sg:person.01137555054.70
93 rdf:rest N0f93e99dc71d4f0c9948dfe518fbc695
94 N39b59388255249f99628d713bae625f4 schema:name pubmed_id
95 schema:value 25146692
96 rdf:type schema:PropertyValue
97 N3e0715a8abd149ab8975c144acedf636 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Aged
99 rdf:type schema:DefinedTerm
100 N43e5cddf19eb46e98a8791a87b063a58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Drug Interactions
102 rdf:type schema:DefinedTerm
103 N46218d9b82a04499baf909f011565a0e rdf:first sg:person.01002361140.23
104 rdf:rest Ned297d75234245768df16693dd332d0d
105 N47c701b4d5264e839898d1a980c95222 rdf:first sg:person.01364605124.29
106 rdf:rest Nca062eb9bebc4946998ead02b7048b0b
107 N488739562830472faa5c567065dcb6a0 schema:affiliation https://www.grid.ac/institutes/grid.418236.a
108 schema:familyName Guta
109 schema:givenName Phyllis
110 rdf:type schema:Person
111 N4ab2d2dc28324157a48bccedcb0cb62d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Drug Combinations
113 rdf:type schema:DefinedTerm
114 N521ead0d74cb4769a727f7787af7ad69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Male
116 rdf:type schema:DefinedTerm
117 N52270c680b4b4ba3bdce67c34f79a65a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Models, Biological
119 rdf:type schema:DefinedTerm
120 N5242485e2d424077b130f6e77bd4d4ad rdf:first sg:person.0575606363.86
121 rdf:rest N9a6bc9f16859490fa955bb5090acce45
122 N53d0878d58494050a9c2fdb61186f8c6 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
123 rdf:type schema:Organization
124 N5728cbc9224c4d0799dd3c5b0c51abf2 rdf:first sg:person.01075710535.47
125 rdf:rest Nfbb625553f004a45863659d3a7ef4c26
126 N5b15802c52314a059c051fefef9d0c21 rdf:first sg:person.0741434051.90
127 rdf:rest N5242485e2d424077b130f6e77bd4d4ad
128 N6a87277eaa0d474aaf8d67035ef3acfe schema:name doi
129 schema:value 10.1007/s00228-014-1732-8
130 rdf:type schema:PropertyValue
131 N6a880b05500a4a9ca6c2f7be9fade2ee schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 N6b45d64f548948759b428404862ac4f0 schema:issueNumber 10
134 rdf:type schema:PublicationIssue
135 N6bd7203992414659908f14d2b2e2edb4 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
136 rdf:type schema:Organization
137 N7b15bfe779074162936ef2cd2f8af0d2 schema:name readcube_id
138 schema:value cebb2057897e46861b5d520c8c6df7cad23cc8a3d453de92848f861b6ca83936
139 rdf:type schema:PropertyValue
140 N84511853986a4a0088fcdd14f0f5c072 rdf:first sg:person.011235763662.85
141 rdf:rest Nbb3b0db2a1a64f258e5f4481def9742b
142 N881b90cee7534836be51e4188e265281 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
143 rdf:type schema:Organization
144 N910c9277120846b088c634dc2f53d36f schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
145 rdf:type schema:Organization
146 N983e69f1d641453bbca58990ff3ec23d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Middle Aged
148 rdf:type schema:DefinedTerm
149 N9a6bc9f16859490fa955bb5090acce45 rdf:first sg:person.01272345137.07
150 rdf:rest N01a032debbd04ec0a0781e0925aac432
151 N9bf9efc16f4d42b8b347e0f005fd133a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Benzoxazines
153 rdf:type schema:DefinedTerm
154 Nb4e88f344b9f4ba2a84c753bfbe44247 rdf:first sg:person.01316471724.72
155 rdf:rest N46218d9b82a04499baf909f011565a0e
156 Nbb3b0db2a1a64f258e5f4481def9742b rdf:first sg:person.01100274674.19
157 rdf:rest rdf:nil
158 Nbe4eaa820c4243c6acf710f5ea214c9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Cross-Over Studies
160 rdf:type schema:DefinedTerm
161 Nc539f10da7ff4d3a99f82e3953a70245 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
162 rdf:type schema:Organization
163 Nc6264a5329f54589bf99c7586ccf2ea6 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
164 rdf:type schema:Organization
165 Nc863e6e0e7b74d19b462c5ad24b38e9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Area Under Curve
167 rdf:type schema:DefinedTerm
168 Nca062eb9bebc4946998ead02b7048b0b rdf:first sg:person.0731212511.71
169 rdf:rest Nb4e88f344b9f4ba2a84c753bfbe44247
170 Ncf43988fcb83402d8fcb8114bf29df81 schema:name nlm_unique_id
171 schema:value 1256165
172 rdf:type schema:PropertyValue
173 Ndfb56bb01dca4e46b42d9d4747d781d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name HIV Integrase Inhibitors
175 rdf:type schema:DefinedTerm
176 Ndfc0208c24b1420b9aaefdd133e27643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Female
178 rdf:type schema:DefinedTerm
179 Ne3c8f1b6cf254c0ca39027bb604bc7a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Ritonavir
181 rdf:type schema:DefinedTerm
182 Ne523682b68b14c189be52f0537555ea2 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
183 rdf:type schema:Organization
184 Neb764dcf03eb46f48c7251e6f3cb1096 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Heterocyclic Compounds, 3-Ring
186 rdf:type schema:DefinedTerm
187 Ned297d75234245768df16693dd332d0d rdf:first sg:person.01317322142.96
188 rdf:rest N2dba33752edc4092a6500ef38cac999b
189 Nf1852d3f52f94307a71b0686e48664b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Anti-HIV Agents
191 rdf:type schema:DefinedTerm
192 Nf1911e3edd2a4edf97f3bc21bad8c3e0 schema:volumeNumber 70
193 rdf:type schema:PublicationVolume
194 Nf9d84629c2884b9fb8c5fab28c5c071e schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
195 rdf:type schema:Organization
196 Nfbb625553f004a45863659d3a7ef4c26 rdf:first sg:person.07374132774.32
197 rdf:rest N47c701b4d5264e839898d1a980c95222
198 Nfc55ad544d304370ac77a9a36d0c1541 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
199 rdf:type schema:Organization
200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
201 schema:name Medical and Health Sciences
202 rdf:type schema:DefinedTerm
203 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
204 schema:name Clinical Sciences
205 rdf:type schema:DefinedTerm
206 sg:journal.1054337 schema:issn 0031-6970
207 1432-1041
208 schema:name European Journal of Clinical Pharmacology
209 rdf:type schema:Periodical
210 sg:person.01002361140.23 schema:affiliation Nf9d84629c2884b9fb8c5fab28c5c071e
211 schema:familyName Castellino
212 schema:givenName Stephen
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002361140.23
214 rdf:type schema:Person
215 sg:person.01075710535.47 schema:affiliation N53d0878d58494050a9c2fdb61186f8c6
216 schema:familyName Lou
217 schema:givenName Yu
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075710535.47
219 rdf:type schema:Person
220 sg:person.01100274674.19 schema:affiliation N881b90cee7534836be51e4188e265281
221 schema:familyName Piscitelli
222 schema:givenName Stephen C.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100274674.19
224 rdf:type schema:Person
225 sg:person.011235763662.85 schema:affiliation https://www.grid.ac/institutes/grid.418236.a
226 schema:familyName Rubio
227 schema:givenName Justin P.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011235763662.85
229 rdf:type schema:Person
230 sg:person.01137555054.70 schema:affiliation https://www.grid.ac/institutes/grid.418236.a
231 schema:familyName Hosking
232 schema:givenName Louise
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137555054.70
234 rdf:type schema:Person
235 sg:person.01234343615.46 schema:affiliation N0bc4ab2127e843ccb4cc8df6e27fb5cf
236 schema:familyName Mosteller
237 schema:givenName Michael
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234343615.46
239 rdf:type schema:Person
240 sg:person.01272345137.07 schema:affiliation Nc539f10da7ff4d3a99f82e3953a70245
241 schema:familyName Chen
242 schema:givenName Shuguang
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272345137.07
244 rdf:type schema:Person
245 sg:person.01316471724.72 schema:affiliation N910c9277120846b088c634dc2f53d36f
246 schema:familyName Peppercorn
247 schema:givenName Amanda
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316471724.72
249 rdf:type schema:Person
250 sg:person.01317322142.96 schema:affiliation N14b058f26c5540c285571de86d29c9a8
251 schema:familyName Wagner
252 schema:givenName David
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317322142.96
254 rdf:type schema:Person
255 sg:person.01364605124.29 schema:affiliation https://www.grid.ac/institutes/grid.419164.f
256 schema:familyName Wajima
257 schema:givenName Toshihiro
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364605124.29
259 rdf:type schema:Person
260 sg:person.0575606363.86 schema:affiliation Nfc55ad544d304370ac77a9a36d0c1541
261 schema:familyName Borland
262 schema:givenName Julie
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575606363.86
264 rdf:type schema:Person
265 sg:person.0731212511.71 schema:affiliation N6bd7203992414659908f14d2b2e2edb4
266 schema:familyName Savina
267 schema:givenName Paul
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731212511.71
269 rdf:type schema:Person
270 sg:person.07374132774.32 schema:affiliation Ne523682b68b14c189be52f0537555ea2
271 schema:familyName Wilfret
272 schema:givenName David
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07374132774.32
274 rdf:type schema:Person
275 sg:person.0741434051.90 schema:affiliation Nc6264a5329f54589bf99c7586ccf2ea6
276 schema:familyName Song
277 schema:givenName Ivy
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741434051.90
279 rdf:type schema:Person
280 sg:pub.10.2165/00003088-200140120-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048700706
281 https://doi.org/10.2165/00003088-200140120-00002
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1016/j.antiviral.2009.09.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022449206
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1016/s0140-6736(12)61853-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045841940
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1016/s0140-6736(13)61221-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022615950
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1016/s1473-3099(11)70290-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012328949
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1021/js970486q schema:sameAs https://app.dimensions.ai/details/publication/pub.1014403362
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1097/qai.0b013e318183a982 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030792638
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1097/qai.0b013e318276cda9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013562829
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1111/j.1365-2125.2011.03947.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028679510
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1124/dmd.112.048918 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045191601
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1128/aac.00073-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025297073
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1128/aac.00292-13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046871169
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1128/aac.00842-09 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012666122
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1128/aac.01486-08 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050895815
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1128/aac.05739-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006959899
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1177/0091270010371113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017710989
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1310/rrx7-49me-27v7-mwwv schema:sameAs https://app.dimensions.ai/details/publication/pub.1064986057
314 rdf:type schema:CreativeWork
315 https://doi.org/10.7448/ias.15.6.18112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049897586
316 rdf:type schema:CreativeWork
317 https://www.grid.ac/institutes/grid.418236.a schema:alternateName GlaxoSmithKline (United Kingdom)
318 schema:name GlaxoSmithKline, Stevenage, UK
319 GlaxoSmithKline, Stockley Park, Uxbridge, UK
320 rdf:type schema:Organization
321 https://www.grid.ac/institutes/grid.419164.f schema:alternateName Shionogi (Japan)
322 schema:name Shionogi & Co., Ltd., Osaka, Japan
323 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...